DOJ Antitrust Division Announces Deferred Prosecution Agreements with Two Pharmaceutical Companies Containing “Extraordinary” Divestiture Remedy
Article
United States: Pharmaceutical Antitrust 2024
Alert
Where Things Stand on Drug Pricing at the Halfway Point of 2023
Insight
European biotech enjoys a burst of dealmaking activity
M&A Explorer | The first quarter saw a string of transactions after a punishing year for the sector
Insight
Tech continues to dominate
Last year was a volatile 12 months for the tech sector, with a steep sell-off in growth stocks and a drop in IPOs—but, although the sector was down, it was by no means out
Alert
EU Court of Justice clarifies that all exchanges with external counsel are privileged – an important development amidst a dawn raid uptick in Europe
Insight
PMB performs as pharma groups repurpose their portfolios
After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention
Insight
Global healthcare M&A delivers strong performance
M&A Explorer | Dealmaking in the pharma, medical and biotech (PMB) subsectors was driven by both old and new market trends in 2022
Alert
Five Drug Pricing Issues to Watch in 2023
Alert
Strong Medicine: Using Investment Treaties to Mitigate Foreign Regulatory Risk in the Life Sciences
Article
United States: Pharmaceutical Antitrust 2023
Alert
2022 Drug Pricing Update: States Continue Legislative Push Even As Congress Passes Long Sought Changes
Insight
Big pharma firms return to the deal table in H1
Cash-rich pharma firms look set for a buying spree, as favorable biotech valuations and patent expirations incentivize dealmaking
Alert
EU General Court confirms European Commission's Article 22 EUMR referral policy
Alert
Federal Legislators and FTC Keep PBMs Center Stage in Drug Pricing Debate
Alert
Smart Cities
At its core, the smart city is about people and improving the quality of our everyday lives.
Alert
Biogen rehearing denied: Is SCOTUS the next step?
Alert
Federal District Court holds that California's anti reverse payment law is enforceable, but only against settlements "negotiated, completed, or entered" in California
Insight
Pharma and healthcare deliver strong results
Despite the absence of megadeals, M&A in the sector climbed from 2020 levels thanks in part to strong PE and SPAC activity
Alert
Drug Pricing Issues to Watch in 2022
Insight
Healthcare M&A on track to set new record in 2021
Heightened interest in medical suppliers, contract research organizations and biotech firms resulted in an impressive year for healthcare dealmaking.
Article
Lexology GTDT: EU Antitrust Developments in the Pharmaceutical Sector
Article
United States: Pharmaceutical Antitrust 2022
Webinar
Global pharmaceuticals: New horizons in a post-COVID world
